Alzamend Neuro, Inc. cotiza a 1.35 USD y tiene una capitalización bursátil de $7M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's,…
| Periodo | 2026-09 | 2026-07 | 2026-03 | 2025-12 |
|---|---|---|---|---|
| Real | $-0.68 | $-0.74 | $-0.58 | $-0.30 |
| Estimado | $-0.56 | $-0.67 | $-0.53 | $-1.95 |
| Sorpresa | -21.4% | -10.4% | -9.4% | +84.6% |
| Métrica | ALZN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -1196.4% | -40.4% | -1156.0% |
| ROA | -421.9% | -32.0% | -389.9% |
| Current Ratio | — | 2.84 | — |
| Debt / Equity | — | 0.28 | — |